Rapid and easy detection of the five most common mutations in BRCA1 and BRCA2 genes in the Polish population using CAPS and ACRS-PCR methods

  • Adam Dąbrowski Laboratory of Molecular Diagnostics "Bio-Genetik" NZOZ, Gliniana 40A, 50-525 Wrocław, Poland
  • Stanisław Ułaszewski Institute of Genetics and Microbiology, University of Wroclaw, Przybyszewskiego 63/77, 51-148 Wroclaw, Poland
  • Katarzyna Niedźwiecka Institute of Genetics and Microbiology, University of Wroclaw, Przybyszewskiego 63/77, 51-148 Wroclaw, Poland http://orcid.org/0000-0003-4482-4784
Keywords: BRCA1 mutatations, BRCA2 mutatations, molecular diagnostics, CAPS, ACRS-PCR


In this publication we present a fast method of diagnosing the most common polymorphisms of BRCA1 and BRCA2 genes in Poland – C61G [c.300T>G], C64R [c.190T>C], 4153delA [c.4035delA], 3819del5 [c.3700_3704delGTAAA], and C5972T [c.5744C>T]. Our procedure is based on the use of the cleaved amplified polymorphic sequences (CAPS) and artificially created restriction site (ACRS) PCR techniques. The precise selection of appropriate primer sequences and restriction enzymes enabled specific cuts of DNA fragments. The final quantity and size of the obtained products depend on the presence or the absence of the mutations. The obtained results are unambiguous and do not have to be confirmed by sequencing. The methods of detection of the C61G, C64R, 4153delA, 3819del5, and C5972T mutations in the BRCA1 and BRCA2 genes described by us do not require a sequencing process, which is more expensive, time-consuming and associated with numerous errors. The technique developed by us enables the use of simple electrophoresis for accurate detection of the presence or absence of a specific mutation. Our procedures are fast, precise and unambiguous.


Antoniou AC, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Hopper JL, Olsson H, Johannsson O, Manoukian S, Eccles DM, Tang N, Olah E, Warner et al (2005) Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 42: 602–603. https://doi.org/10.1136/jmg.2004.024133

Brozek I, Cybulska C, Ratajska M, Piatkowska M, Kluska A, Balabas A, Dabrowska M, Nowakowska D, Niwinska A, Pamula-Pilat J, Tecza K, Pekala W, Rembowska J, Nowicka K, Mosor M, Januszkiewicz-ewandowska D, Rachtan J, Grzybowska E, Nowak J et al (2011) Prevalence of the most frequent BRCA1 mutations in Polish population. J Appl Genet 52: 325–330. https://doi.org/10.1007/s13353-011-0040-6

Brozek I, Ratajska M, Piatkowska M, Kluska A, Balabas A, Dabrowska M, Nowakowska D, Niwinska A, Rachtan J, Steffen J, Limon J (2012) Limited significance of family history for presence of BRCA1 gene mutation in Polish breast and ovarian cancer cases. Fam Cancer 11: 351–354. https://doi.org/10.1007/s10689-012-9519-5

Celebiler Cavusoglu A, Kilic Y, Saydam S, Canda T, Baskan Z, Sevinc AI, Sakizli M (2009) Predicting invasive phenotype with CDH1, CDH13, CD44, and TIMP3 gene expression in primary breast cancer. Cancer Sci 100: 2341–2345. https://doi.org/10.1111/j.1349-7006.2009.01333.x

Domchek SM, Tang J, Stopfer J, Lilli DR, Hamel N, Tischkowitz M, Monteiro ANA, Messick TE, Powers J, Yonker A, Couch FJ, Goldgar DE, Davidson HR, Nathanson KL, Foulkes WD, Greenberg RA (2014) Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer. Cancer Discov 3: 399–405. https://doi.org/10.1158/2159-8290.CD-12-0421

Dubrovska A, Kanamoto T, Lomnytska M, Heldin C-H, Volodko N, Souchelnytskyi S (2005) TGFbeta1/Smad3 counteracts BRCA1-dependent repair of DNA damage. Oncogene 24: 2289–2297. https://doi.org/10.1038/sj.onc.1208443

Górski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, Mackiewicz H, Niepsuj S, Góźdź S, Zaremba L, Posmyk M, Płużańska M, Kilar E, Czudowska D, Waśko B, Miturski R, Kowalczyk JR, Urbański K, Szwiec M et al (2004) A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int. J Cancer 110: 683–686. https://doi.org/10.1002/ijc.20162

Górski B, Narod SA, Lubiński J (2005) A common missense variant in BRCA2 predisposes to early onset breast cancer. Breast Cancer Res 7: R1023-7. https://doi.org/10.1186/bcr1338

Grzybowska E, Siemińska M, Zientek H, Kalinowska E, Michalska J, Utracka-hutka B, Rogozińska-Szczepka J, Kaźmierczak-Maciejewska M (2002) Germline mutations in the BRCA1 gene predisposing to breast and ovarian cancers in Upper Silesia population. Acta Biochem Pol 49: 351–356

Hosseini SY, Sabahi F, Amini-Bavil-Olyaee S, Alavian S-M, Merat S (2006) A novel accurate ACRS-PCR method with a digestion internal control for identification of wild type and YMDD mutants of hepatitis B virus strains. J Virol Methods 137: 298–303. https://doi.org/10.1016/j.jviromet.2006.07.008

Hyman DM, Zhou Q, Iasonos A, Grisham RN, Arnold AG, Phillips MF, Bhatia J, Levine DA, Aghajanian C, Offit K, Barakat RR, Spriggs DR, Kauff ND (2013) Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 118: 3703–3709. https://doi.org/10.1002/cncr.26655

Karami F, Mehdipour P (2013) A Comprehensive Focus on Global Spectrum of BRCA1 and BRCA2 Mutations in Breast Cancer. Biomed Res Int 2013: 1–21. https://doi.org/10.1155/2013/928562

Kirchhoff T, Kauff ND, Mitra N, Nafa K, Huang H, Palmer C, Gulati T, Wadsworth E, Donat S, Robson ME, Ellis NA, Offit K (2004) BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews. Clin Cancer Res 10: 2918–2921. https://doi.org/10.1158/1078-0432.CCR-03-0604

Liu C-Y, Flesken-Nikitin A, Li S, Zeng Y, Lee W-H (1996) Inactivation of the mouse Brcal gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes Dev 10: 1835–1843. https://doi.org/10.1101/gad.10.14.1835

Mersch J (2016) Cancers Associated with BRCA1 and BRCA2 Mutations other than Breast and Ovarian. Cancer 121: 269–275. https://doi.org/10.1002/cncr.29041

Musolino A, Bella MA, Bortesi B, Michiara M, Naldi N, Zanelli P, Capelletti M, Pezzuolo D, Camisa R, Savi M, Neri TM, Ardizzoni A (2007) BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study. Breast 16: 280–292. https://doi.org/10.1016/j.breast.2006.12.003

Nunziato M, Starnone F, Lombardo B, Pensabene M, Condello C, Verdesca F, Carlomagno C, De Placido S, Pastore L, Salvatore F, D’Argenio V (2017) Fast Detection of a BRCA2 Large Genomic Duplication by Next Generation Sequencing as a Single Procedure : A Case Report. Int J Mol Sci 18: 1–9. https://doi.org/10.3390/ijms18112487

Schorge JO, Modesitt SC, Coleman RL, Cohn DE, Kauff ND, Duska LR, Herzog TJ (2010) SGO White Paper on Ovarian Cancer: Etiology, Screening and Surveillance. Gynecol Oncol Elsevier Inc. 119: 7–17. https://doi.org/10.1016/j.ygyno.2010.06.003

Siegel R, Naishadham D, Jemal A (2013) Cancer Statistics, 2013. CA Cancer J Clin 63: 11–30. https://doi.org/10.3322/caac.21166

Siegel RL, Miller KD, Jemal A (2016) Cancer Statistics , 2016. CA Cancer J Clin 66: 7–30. https://doi.org/10.3322/caac.21332

Silver DP, Livingston DM (2012) Mechanisms of BRCA1 Tumor Suppression. Cancer Discov 2: 679–684. https://doi.org/10.1158/2159-8290.CD-12-0221

Smith KR, Hanson HA, Hollingshaus MS (2013) BRCA1 and BRCA2 mutations and female fertility. Curr Opin Obstet Gynecol 25: 207–213. https://doi.org/10.1097/GCO.0b013e32835f1731

Suryavanshi M, Kumar D, Kumar Panigrahi M, Chowdhary M, Mehta A (2017) Detection of false positive mutations in BRCA gene by next generation sequencing. Fam Cancer 16: 311–317. https://doi.org/10.1007/s10689-016-9955-8

Zheng L, Li S, Boyer TG, Lee W-H (2000) Lessons learned from BRCA1 and BRCA2. Oncogene 19: 6159–6175. https://doi.org/10.1038/sj.onc.1203968